Skip to main content


Latest articles

24-09-2021 | Oncology | News | Article

Long-term effects of COVID-19 not uncommon in cancer patients

Around one in seven people with cancer and COVID-19 report persistent symptomatic sequelae of the infection after recovery, suggest data from the OncCOVID study.

24-09-2021 | Oncology | News | Article

Combining LuPSMA with pembrolizumab ‘promising’ for mCRPC

Results of the PRINCE trial point to the potential of LuPSMA plus pembrolizumab for the treatment of metastatic castration-resistant prostate cancer with high expression of PSMA.

23-09-2021 | Oncology | News | Article

MONALEESA-2 update demonstrates ribociclib plus letrozole OS benefit

The final overall survival findings from the MONALEESA-2 trial confirm the long-term benefits of combining ribociclib with first-line letrozole for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer.

22-09-2021 | Oncology | News | Article

CASPIAN update cements durvalumab–chemo as standard of care for extensive-stage SCLC

The overall survival advantage offered by the use of durvalumab alongside first-line chemotherapy in people with extensive-stage small-cell lung cancer is sustained over time, suggests the 3-year follow-up of the CASPIAN study.

22-09-2021 | Oncology | News | Article

Adequate response to COVID-19 vaccine in people receiving anticancer therapy

Administration of two doses of the Moderna vaccine against COVID-19 elicits an adequate immune response in most, but not all, patients with a solid tumor treated with chemotherapy, immunotherapy, or both, indicate findings.

21-09-2021 | Oncology | News | Article

Drug-free interval feasible in metastatic RCC

Incorporating a drug-free interval into first-line treatment for metastatic clear cell renal cell carcinoma may not be detrimental to patient survival or quality of life, suggest STAR trial data presented at the ESMO Congress 2021.

Image Credits